The Future of Obesity Science: What's Coming After GLP-1

For most of the 20th century, pharmacological approaches to obesity produced modest results with significant side effects — a history of failures (fen-phen, sibutramine, rimonabant) that created justified skepticism about weight loss drugs. The GLP-1 era changed this calculus fundamentally. Semaglutide and tirzepatide produce weight loss that approaches or overlaps with bariatric surgery at the best doses, with side effect profiles that are manageable for most patients. But the field is not standing still. The pipeline of next-generation obesity treatments is more active than at any point in the history of metabolic medicine.

Where the current generation stands

Semaglutide 2.4mg (Wegovy) produces approximately 15% body weight loss on average in the STEP 1 trial. Tirzepatide 15mg (Zepbound), a dual GLP-1/GIP agonist, achieved 20.9% average weight loss in SURMOUNT-1 — the highest weight loss ever recorded in a randomized pharmaceutical trial of a non-surgical intervention. For the mechanistic explanation of how tirzepatide's dual agonism works, see our full breakdown. For semaglutide's mechanism specifically, see that guide.

These are remarkable outcomes. They are also not the ceiling. Bariatric surgery still achieves 25–35% weight loss at 10-year follow-up, and both current medications produce weight regain when discontinued. The research community is pushing hard on both fronts: greater efficacy and more durable outcomes.

Triple agonists: GLP-1 + GIP + glucagon

The next pharmaceutical wave beyond dual agonists is triple agonism. Retatrutide (Eli Lilly) simultaneously activates GLP-1, GIP, and glucagon receptors. The inclusion of glucagon receptor agonism is strategically significant: glucagon increases energy expenditure (a mechanism absent in pure GLP-1/GIP agonists), potentially addressing the metabolic adaptation side of weight management rather than just the appetite side.

Phase 2 data published in the New England Journal of Medicine in 2023 showed average weight loss of approximately 24% at 36 weeks — exceeding tirzepatide's 48-week results in a shorter timeframe. If Phase 3 data confirms this, retatrutide would represent a meaningful step beyond the current leading agents. The key challenge is the glucagon component: glucagon is catabolic and can cause nausea, potential muscle loss, and hepatic effects at higher doses. Calibrating the therapeutic window to achieve metabolic benefits without excessive catabolism is the primary formulation challenge.

Amylin analogs and combination strategies

Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It promotes satiety through mechanisms distinct from GLP-1 — acting on different hypothalamic nuclei and brainstem receptors. This mechanistic complementarity makes amylin agonism an attractive combination partner for GLP-1 therapy.

Cagrilintide is a long-acting amylin analog in Phase 3 development. The combination of cagrilintide and semaglutide ("CagriSema") produced approximately 15% weight loss over 32 weeks in Phase 2 data — notable not for the absolute magnitude but for the distinct mechanism and potentially complementary side-effect profile. Full Phase 3 results will determine whether the combination offers meaningful advantages over high-dose tirzepatide monotherapy.

Oral GLP-1 formulations

Injectable administration remains a barrier for some patients, both logistically and psychologically. Oral semaglutide already exists (Rybelsus, approved for type 2 diabetes) but has approximately 1% bioavailability compared to subcutaneous injection — a limitation driven by rapid degradation in the gastrointestinal tract and poor membrane permeability of the peptide molecule.

Novo Nordisk has developed next-generation oral formulations using absorption enhancers (SNAC technology) with improved bioavailability. Early trial data suggests efficacy approaching injectable Wegovy at optimized doses. Eli Lilly's oral tirzepatide is also in Phase 3 development. If Phase 3 data confirms non-inferiority to injectables, oral GLP-1 agonists would dramatically expand access — removing the injection barrier for patients who decline or cannot manage subcutaneous administration.

Central nervous system targets

A different research frontier targets the brain's energy regulation centers directly, rather than gut hormone pathways. The melanocortin system — specifically the MC4R (melanocortin receptor 4) pathway in the hypothalamus — is the most studied central target. MC4R is the most common single-gene cause of severe early-onset obesity; mutations cause hyperphagia and obesity through impaired hypothalamic satiety signaling.

Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for patients with specific genetic deficiencies in the MC4R pathway (POMC, PCSK1, or LEPR gene deficiencies). Its approved population is currently narrow, but research into broader melanocortin pathway interventions is ongoing.

More speculatively, research into neuroplasticity in the hypothalamus — the idea that the brain's defended weight set point can be genuinely reset rather than merely overridden — represents a longer-horizon scientific frontier. Some obesity researchers hypothesize that combination approaches targeting both gut hormone pathways and central neuroplasticity may be necessary for permanent metabolic reset. This is not yet a clinical reality, but it is a theoretically coherent next frontier.

Precision medicine and pharmacogenomics

A consistent observation in GLP-1 clinical trials is substantial individual variation in response: approximately 5–10% of participants lose minimal weight even at maximum doses, while others lose 30–35% — far above the trial average. Current medicine has no reliable way to predict which category a given patient falls into before starting treatment.

Pharmacogenomic research is beginning to identify genetic variants in GLP-1 receptor signaling pathways, gut motility genes, and reward circuit genes that may predict response magnitude. If validated at clinical scale, genetic testing before prescribing could match patients to the agent most likely to work for their specific biology, reducing trial-and-error and improving outcomes. This is a 5–10 year research horizon rather than an immediate clinical tool.

Bariatric surgery and the GLP-1 connection

A critical insight from bariatric surgery research illuminates the future of obesity pharmacology: much of bariatric surgery's efficacy appears to work through the same hormonal mechanisms that GLP-1 drugs target. Roux-en-Y gastric bypass dramatically increases post-meal GLP-1 and PYY secretion by rerouting food directly to the distal small intestine, where L-cell density is highest. The surgery's appetite effects are largely hormonal, not mechanical.

This understanding is driving research into "gut hormone surgery" — procedures designed to achieve bariatric-like hormonal outcomes without the anatomical complexity of full gastric bypass. It also suggests that the pharmacological ceiling may be higher than current drugs have yet achieved, if the full post-bariatric hormonal environment can be replicated chemically. For what long-term outcomes look like with current best practices, see Sustainable Weight Management.

Frequently asked questions

What is the most promising next obesity drug after tirzepatide?

Retatrutide (triple GLP-1/GIP/glucagon agonist, Eli Lilly) showed approximately 24% weight loss in Phase 2 trials — potentially the highest efficacy ever seen in a non-surgical obesity treatment. Phase 3 trials are ongoing. Oral GLP-1 formulations (from both Novo Nordisk and Eli Lilly) are also in late development and would significantly expand access by removing the injection barrier.

Will there ever be a cure for obesity?

The scientific community increasingly views obesity as a chronic condition requiring ongoing management rather than a disease with a one-time cure. Current medications are highly effective while used but do not permanently reset the defended weight set point. Research into neuroplasticity and central regulatory mechanisms may eventually produce more permanent interventions, but this is a long-horizon scientific goal rather than an imminent clinical development.

How close is an effective oral GLP-1 medication?

Phase 3 trials for oral semaglutide (at weight-management doses) and oral tirzepatide are underway as of 2025–2026. If data is positive and FDA approval follows, effective oral GLP-1 formulations could reach the market within 2–4 years. This would be a significant access expansion — removing the primary barrier for many patients who decline injectable treatment.

Will GLP-1 medications be affordable long-term?

Brand-name GLP-1 medications currently cost $800–$1,400/month in the US without insurance. Generic semaglutide and tirzepatide are not yet available, but patent expirations and the entry of biosimilars are expected to substantially reduce prices over the next 5–10 years. Oral formulations, if approved, may also have different cost structures than injectables. Global access remains a major equity challenge regardless of US pricing trends.

We are almost certainly at the beginning of a pharmacological revolution in metabolic medicine — not the end of one. The next decade will likely produce interventions that make today's breakthrough drugs look like the first generation they are.